[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345200-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345200-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","epigenetic-silencing-of-dlec1-correlates-with-tumor-immune-microenvironment-and-predicts-immunotherapy-prognosis-in-multiple-cancers","Epigenetic silencing of DLEC1 correlates with tumor immune microenvironment and predicts immunotherapy prognosis in multiple cancers","","Cancer remains a major health issue globally, with rising incidence and mortality. Immunotherapy has transformed cancer care, yet response rates vary, making predictive biomarkers essential. This study uses public datasets and tumor samples to assess DLEC1 expression and promoter hypermethylation in normal versus cancer tissues, and evaluates its prognostic and immunotherapy marker potential. Functional experiments in breast cancer models show DLEC1 inhibits proliferation, induces apoptosis, and activates interferon lambda signaling.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/epigenetic-silencing-of-dlec1-correlates-with-tumor-immune-microenvironment-and-predicts-immunotherapy-prognosis-in-multiple-cancers/345200/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/epigenetic-silencing-of-dlec1-correlates-with-tumor-immune-microenvironment-and-predicts-immunotherapy-prognosis-in-multiple-cancers/345200.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What biomarker did the study focus on, and what molecular changes were examined?","Question",{"text":63,"@type":64},"The study focused on DLEC1 and examined its expression along with promoter hypermethylation in normal and tumor tissues.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did DLEC1 relate to cancer prognosis and immune responses?",{"text":68,"@type":64},"DLEC1 downregulation and methylation were observed across multiple cancers. High DLEC1 expression correlated with better prognosis and increased immune cell infiltration, and patients showed improved survival under immune checkpoint inhibitor therapies.",{"name":70,"@type":61,"acceptedAnswer":71},"What functional effects were found for DLEC1 in breast cancer models?",{"text":72,"@type":64},"In breast cancer cell lines, DLEC1 inhibited tumor cell proliferation, induced apoptosis, and activated interferon lambda1 signaling, supporting a tumor-suppressive and immunoregulatory role.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345200,1790648390,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Human Genetics (2026) 145:40  \n[https://doi.org/10.1007/s00439-026-02828-3](https://doi.org/10.1007/s00439-026-02828-3)  \nORIGINAL INVESTIGATION  \nEpigenetic silencing of DLEC1 correlates with tumor immune microenvironment and predicts immunotherapy prognosis in multiple cancers  \nRuijie Ming1,2 · Qi Xiong1 · Shuh-Ying Tan3 · Lili Li4 · Shujie Bao4 · Jianhua Wang1 · Lijuan Zhao1 · Xiaoqian He1 · Zeze Zheng1 · Yan Wang1 · Xiaoyu Liu2 · Jun Tang1 · Zhongjun Wu1 · Tingxiu Xiang1,2 · Qian Tao1,3,4  \nReceived: 8 October 2025 / Accepted: 16 March 2026 © The Author(s) 2026, modified publication 2026  \nAbstract  \nCancer remains a major health issue globally, with increasing incidence and mortality rates. While immunotherapy has revolutionized cancer treatment, not all patients benefit, urging the identification of predictive biomarkers. This study utilized public datasets and tumor samples to examine the expression and promoter hypermethylation of DLEC1 in normal and tumor tissues, to evaluate its potential as prognostic and immunotherapy marker. In vitro and in vivo experiments on breast cancer (BrCa) cell lines were conducted to explore the functions and mechanisms of DLEC1 . The prognostic significance ofDLEC1 downregulation and its impact on immune cell infiltration and immunotherapy efficacy were analyzed using the GEO and TCGA databases. DLEC1 was frequently downregulated and methylated across multiple cancers. In BrCa, expression of DLEC1 inhibited tumor cell proliferation, induced apoptosis, and activated the interferon lambda1 signaling pathway, indicating its important role as a bona fide tumor suppressor and immunoregulator. High DLEC1 expression correlated with better prognosis in several cancer types and with increased immune cell infiltration. Cancer patients with high DLEC1 expression showed improved overall and progression-free survival under immune checkpoint inhibitor therapies, such as anti-CTLA4, anti-PD1 and anti-PDL1 . DLEC1 promoter hypermethylation is a promising biomarker for cancer prognosis and potential immunotherapy response prediction. Its expression and promoter hypermethylation status could thus help to guide clinical treatment strategies for cancer patients, particularly of breast cancer.  \nRuijie Ming and Qi Xiong have contributed equally to this work and share first authorship.  \n􀀍 Tingxiu Xiang [xiangtx@cqmu.edu.cn](xiangtx@cqmu.edu.cn)  \n􀀍 Qian Tao [qtao@cuhk.edu.hk](qtao@cuhk.edu.hk)  \n1 Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400030, China  \n2 Chongqing Key Laboratory for the Mechanism and Intervention of Cancer Metastasis, Chongqing University Cancer Hospital, Chongqing University, Chongqing 400030, China  \n3 Johns Hopkins Singapore, Singapore, Singapore  \n4 Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Translational Oncology and Sir YK Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China  \nIntroduction  \nCancer remains a significant public health challenge globally, with incidence and mortality rates rising annually (International Agency for Research on Cancer) . In 2022, there were ~ 20 million new cases and 9.7 million cancerrelated deaths (Bray et al. 2024) . Traditional cancer treatments include surgery, radiotherapy, chemotherapy, and targeted therapy (Yahya and Alqadhi 2021). In recent years, immunotherapy, particularly immune checkpoint inhibitors, has emerged as a frontline treatment for certain cancers (Larroquette et al. 2021, Akhbariyoon et al. 2021) . However, not all cancer patients benefit from immunotherapy (Donisi et al. 2024), urging the need to develop biomarkers to identify and classify patients likely to respond to immunotherapy. The development of this type of predictive biomarkers is crucial for optimizing clinical treatment strategies and improving outcomes for cancer patients.  \nDeleted in Lung and Esophageal Cancer 1 (DLEC1) is locate","cbCaifi8dpuzPVv5","https://ap.wps.com/l/cbCaifi8dpuzPVv5","pdf",6752886,17,"English","# Introduction\n# Materials and methods","[{\"question\":\"What biomarker did the study focus on, and what molecular changes were examined?\",\"answer\":\"The study focused on DLEC1 and examined its expression along with promoter hypermethylation in normal and tumor tissues.\"},{\"question\":\"How did DLEC1 relate to cancer prognosis and immune responses?\",\"answer\":\"DLEC1 downregulation and methylation were observed across multiple cancers. High DLEC1 expression correlated with better prognosis and increased immune cell infiltration, and patients showed improved survival under immune checkpoint inhibitor therapies.\"},{\"question\":\"What functional effects were found for DLEC1 in breast cancer models?\",\"answer\":\"In breast cancer cell lines, DLEC1 inhibited tumor cell proliferation, induced apoptosis, and activated interferon lambda1 signaling, supporting a tumor-suppressive and immunoregulatory role.\"}]","Epigenetic silencing of DLEC1 correlates with tumor immune microenvironment and predicts immunotherapy prognosis in multiple cancers | PDF",1790056770,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfd2ed9ce0369fa18bda463a79107798.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80add646a5f56f31897f34a94e262eca.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3877d9123859c41aca37536d8c6733fe.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f727d245423b5c4b4ebb7e6ef6b63855.webp",980,1301]